Latest Regulatory Engagement News

Alterity Therapeutics has announced encouraging Phase 2 trial results for ATH434, showing significant slowing of disease progression in multiple system atrophy (MSA) patients and a strong safety profile. These findings mark a potential breakthrough in treating a disease with no approved therapies.

Neurotech International reports key clinical progress in paediatric neurological disorders, securing FDA orphan drug designation for its Rett Syndrome treatment and advancing pivotal trials for ASD and PANDAS/PANS.

PYC Therapeutics reports substantial progress across all four of its drug development programs in Q4 2024, including key regulatory designations and clinical milestones that set the stage for pivotal trials in 2025.

Noronex Limited has lodged applications for two expansive Prospecting Licences in Botswana adjacent to its active Damara Copper Project in Namibia, signaling a strategic push into new, unexplored terrain within the Kalahari Copper Belt.

Actinogen Medical accelerates recruitment in its pivotal XanaMIA Alzheimer's trial while securing a strong cash position of $22.9 million, underpinning its late-stage development and commercial readiness.

Syntara Limited has reported encouraging interim Phase 2 trial results for its lead drug candidate SNT-5505 in myelofibrosis, alongside a successful A$15 million capital raise to advance multiple clinical programs.

OzAurum Resources has made significant strides in its Mulgabbie North Gold Project feasibility study, fully funded by Line Hydrogen Pty Ltd, aiming for a near-term cashflow positive trial operation.

Helios Energy has released an independent Contingent Resource Report confirming substantial recoverable oil, gas, and NGL volumes at its Presidio Project in West Texas, reinforcing its potential as a transformative asset.

Dimerix Limited has inked a lucrative licensing agreement with Fuso Pharmaceutical for its kidney disease drug DMX-200 in Japan, while completing recruitment for its pivotal Phase 3 ACTION3 trial.

Pacific Edge announces a two-month delay in the Medicare Local Coverage Determination for its genetic oncology tests, extending the effective date to April 24, 2025. This extension follows the company’s active engagement with US regulatory bodies.

The Takeovers Panel has declined to investigate Global Lithium Resources Limited's claims of undisclosed shareholder associations ahead of its AGM, citing untimeliness and lack of merit.

EBR Systems has announced a rescheduling of the FDA Pre-Approval Inspection for its wireless cardiac pacing device to January 14, 2025, while maintaining its regulatory approval timeline for Q1 2025 and a commercial launch later in the year.